Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170


Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.

Olmos JM, Hernández JL, Llorca J, Nan D, Valero C, González-Macías J.

J Clin Endocrinol Metab. 2012 Dec;97(12):4491-7. doi: 10.1210/jc.2012-2999. Epub 2012 Oct 5.


Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.

Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.


Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.

Zikan V, Stepan JJ.

Bone. 2009 Apr;44(4):634-8. doi: 10.1016/j.bone.2008.12.013. Epub 2008 Dec 24.


Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.

Recker R, Lips P, Felsenberg D, Lippuner K, Benhamou L, Hawkins F, Delmas PD, Rosen C, Emkey R, Salzmann G, He W, Santora AC.

Curr Med Res Opin. 2006 Sep;22(9):1745-55.


Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.

Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, De Peng Y, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L, Santora AC.

Osteoporos Int. 2015 Sep;26(9):2365-74. doi: 10.1007/s00198-015-3141-y. Epub 2015 May 1. Erratum in: Osteoporos Int. 2015 Nov;26(11):2719-20.


Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.

Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.

J Clin Endocrinol Metab. 2002 Mar;87(3):985-92.


Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.


Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.

Sakai A, Ito M, Tomomitsu T, Tsurukami H, Ikeda S, Fukuda F, Mizunuma H, Inoue T, Saito H, Nakamura T; e-ADVANCED Study Group.

Osteoporos Int. 2015 Mar;26(3):1193-202. doi: 10.1007/s00198-014-2991-z. Epub 2015 Jan 16. Erratum in: Osteoporos Int. 2015 Apr;26(4):1453.


Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.

Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.

J Am Geriatr Soc. 2007 May;55(5):752-7.


Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.

Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.

J Bone Miner Res. 2010 Oct;25(10):2239-50. doi: 10.1002/jbmr.119.


Short-term effects on bone turnover markers of a single high dose of oral vitamin D₃.

Rossini M, Gatti D, Viapiana O, Fracassi E, Idolazzi L, Zanoni S, Adami S.

J Clin Endocrinol Metab. 2012 Apr;97(4):E622-6. doi: 10.1210/jc.2011-2448. Epub 2012 Feb 1.


Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.

Muschitz C, Kocijan R, Fahrleitner-Pammer A, Pavo I, Haschka J, Schima W, Kapiotis S, Resch H.

J Bone Miner Res. 2014 Aug;29(8):1777-85. doi: 10.1002/jbmr.2216.


Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.

Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H.

J Bone Miner Res. 2013 Jan;28(1):196-205. doi: 10.1002/jbmr.1716.


Influence of vitamin D status on the effect of statins on bone mineral density and bone turnover markers in postmenopausal women.

Hernández JL, Olmos JM, Romaña G, Llorca J, Martínez J, Castillo J, de Juan J, Pérez-Pajares I, Ruiz S, González-Macías J.

J Clin Endocrinol Metab. 2014 Sep;99(9):3304-9. doi: 10.1210/jc.2014-1102. Epub 2014 May 30.


Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.

Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.

J Clin Endocrinol Metab. 2013 Dec;98(12):4727-35. doi: 10.1210/jc.2013-2020. Epub 2013 Sep 24.


Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.

Roux C, Binkley N, Boonen S, Kiel DP, Ralston SH, Reginster JY, Pong A, Rosenberg E, Santora A; FOCUS-D Investigators.

Calcif Tissue Int. 2014 Feb;94(2):153-7. doi: 10.1007/s00223-013-9763-1. Epub 2013 Aug 4. Erratum in: Calcif Tissue Int. 2014 Feb;94(2):158. Regnister, Jean-Yves [corrected to Reginster, Jean-Yves].


A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.

Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, Nickelsen T.

J Clin Endocrinol Metab. 2001 Mar;86(3):1212-21. Erratum in: J Clin Endocrinol Metab 2001 Jul;86(7):3008.


Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.

Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R.

J Bone Miner Res. 1998 Jun;13(6):1051-5.


Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.

Tan W, Sun J, Zhou L, Li Y, Wu X.

J Clin Pharm Ther. 2016 Oct;41(5):519-23. doi: 10.1111/jcpt.12429. Epub 2016 Jul 21.


Supplemental Content

Support Center